Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus
- Autores
- Mackern Oberti, Juan Pablo; Obreque, J.; Méndez, G. P.; Llanos, Carolina; Kalergis, Alexis
- Año de publicación
- 2015
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Systemic lupus erythematosus is characterized by the presence of circulating anti-nuclear antibodies (ANA) and systemic damage that includes nephritis, haematological manifestations and pulmonary compromise, among others. Although major progress has been made in elucidating the molecular mechanisms responsible for autoimmunity, current therapies for lupus have not improved considerably. Because the exposure of carbon monoxide (CO) has been shown to display beneficial immunoregulatory properties in different immune-mediated diseases, we investigated whether CO therapy improves lupus-related kidney injury in lupus mice. MRL-Faslpr lupus mice were exposed to CO and disease progression was evaluated. ANA, leucocyte-infiltrating populations in spleen, kidney and lung and kidney lesions, were measured. CO therapy significantly decreased the frequency of activated B220+ CD4- CD8- T cells in kidneys and lungs, as well as serum levels of ANA. Furthermore, we observed that CO therapy reduced kidney injury by decreasing proliferative glomerular damage and immune complexes deposition, decreased proinflammatory cytokine production and finally delayed the impairment of kidney function. CO exposure ameliorates kidney and lung leucocyte infiltration and delays kidney disease in MRL-Faslpr lupus mice. Our data support the notion that CO could be explored as a potential new therapy for lupus nephritis.
Fil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Pontificia Universidad Católica de Chile; Chile
Fil: Obreque, J.. Pontificia Universidad Católica de Chile; Chile
Fil: Méndez, G. P.. Pontificia Universidad Católica de Chile; Chile
Fil: Llanos, Carolina. Pontificia Universidad Católica de Chile; Chile
Fil: Kalergis, Alexis. Pontificia Universidad Católica de Chile; Chile - Materia
-
Carbon monoxide
immunotheraoy
autoimmunity
lupus - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/210329
Ver los metadatos del registro completo
| id |
CONICETDig_b9420d55d8dac1a93ac246843537448a |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/210329 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosusMackern Oberti, Juan PabloObreque, J.Méndez, G. P.Llanos, CarolinaKalergis, AlexisCarbon monoxideimmunotheraoyautoimmunitylupushttps://purl.org/becyt/ford/1.6https://purl.org/becyt/ford/1Systemic lupus erythematosus is characterized by the presence of circulating anti-nuclear antibodies (ANA) and systemic damage that includes nephritis, haematological manifestations and pulmonary compromise, among others. Although major progress has been made in elucidating the molecular mechanisms responsible for autoimmunity, current therapies for lupus have not improved considerably. Because the exposure of carbon monoxide (CO) has been shown to display beneficial immunoregulatory properties in different immune-mediated diseases, we investigated whether CO therapy improves lupus-related kidney injury in lupus mice. MRL-Faslpr lupus mice were exposed to CO and disease progression was evaluated. ANA, leucocyte-infiltrating populations in spleen, kidney and lung and kidney lesions, were measured. CO therapy significantly decreased the frequency of activated B220+ CD4- CD8- T cells in kidneys and lungs, as well as serum levels of ANA. Furthermore, we observed that CO therapy reduced kidney injury by decreasing proliferative glomerular damage and immune complexes deposition, decreased proinflammatory cytokine production and finally delayed the impairment of kidney function. CO exposure ameliorates kidney and lung leucocyte infiltration and delays kidney disease in MRL-Faslpr lupus mice. Our data support the notion that CO could be explored as a potential new therapy for lupus nephritis.Fil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Pontificia Universidad Católica de Chile; ChileFil: Obreque, J.. Pontificia Universidad Católica de Chile; ChileFil: Méndez, G. P.. Pontificia Universidad Católica de Chile; ChileFil: Llanos, Carolina. Pontificia Universidad Católica de Chile; ChileFil: Kalergis, Alexis. Pontificia Universidad Católica de Chile; ChileOxford University Press2015-07info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/210329Mackern Oberti, Juan Pablo; Obreque, J.; Méndez, G. P.; Llanos, Carolina; Kalergis, Alexis; Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus; Oxford University Press; Clinical and Experimental Immunology; 7-2015; 1-130009-9104CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1111/cei.12657info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:59:26Zoai:ri.conicet.gov.ar:11336/210329instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:59:26.425CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| title |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| spellingShingle |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus Mackern Oberti, Juan Pablo Carbon monoxide immunotheraoy autoimmunity lupus |
| title_short |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| title_full |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| title_fullStr |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| title_full_unstemmed |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| title_sort |
Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus |
| dc.creator.none.fl_str_mv |
Mackern Oberti, Juan Pablo Obreque, J. Méndez, G. P. Llanos, Carolina Kalergis, Alexis |
| author |
Mackern Oberti, Juan Pablo |
| author_facet |
Mackern Oberti, Juan Pablo Obreque, J. Méndez, G. P. Llanos, Carolina Kalergis, Alexis |
| author_role |
author |
| author2 |
Obreque, J. Méndez, G. P. Llanos, Carolina Kalergis, Alexis |
| author2_role |
author author author author |
| dc.subject.none.fl_str_mv |
Carbon monoxide immunotheraoy autoimmunity lupus |
| topic |
Carbon monoxide immunotheraoy autoimmunity lupus |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/1.6 https://purl.org/becyt/ford/1 |
| dc.description.none.fl_txt_mv |
Systemic lupus erythematosus is characterized by the presence of circulating anti-nuclear antibodies (ANA) and systemic damage that includes nephritis, haematological manifestations and pulmonary compromise, among others. Although major progress has been made in elucidating the molecular mechanisms responsible for autoimmunity, current therapies for lupus have not improved considerably. Because the exposure of carbon monoxide (CO) has been shown to display beneficial immunoregulatory properties in different immune-mediated diseases, we investigated whether CO therapy improves lupus-related kidney injury in lupus mice. MRL-Faslpr lupus mice were exposed to CO and disease progression was evaluated. ANA, leucocyte-infiltrating populations in spleen, kidney and lung and kidney lesions, were measured. CO therapy significantly decreased the frequency of activated B220+ CD4- CD8- T cells in kidneys and lungs, as well as serum levels of ANA. Furthermore, we observed that CO therapy reduced kidney injury by decreasing proliferative glomerular damage and immune complexes deposition, decreased proinflammatory cytokine production and finally delayed the impairment of kidney function. CO exposure ameliorates kidney and lung leucocyte infiltration and delays kidney disease in MRL-Faslpr lupus mice. Our data support the notion that CO could be explored as a potential new therapy for lupus nephritis. Fil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Pontificia Universidad Católica de Chile; Chile Fil: Obreque, J.. Pontificia Universidad Católica de Chile; Chile Fil: Méndez, G. P.. Pontificia Universidad Católica de Chile; Chile Fil: Llanos, Carolina. Pontificia Universidad Católica de Chile; Chile Fil: Kalergis, Alexis. Pontificia Universidad Católica de Chile; Chile |
| description |
Systemic lupus erythematosus is characterized by the presence of circulating anti-nuclear antibodies (ANA) and systemic damage that includes nephritis, haematological manifestations and pulmonary compromise, among others. Although major progress has been made in elucidating the molecular mechanisms responsible for autoimmunity, current therapies for lupus have not improved considerably. Because the exposure of carbon monoxide (CO) has been shown to display beneficial immunoregulatory properties in different immune-mediated diseases, we investigated whether CO therapy improves lupus-related kidney injury in lupus mice. MRL-Faslpr lupus mice were exposed to CO and disease progression was evaluated. ANA, leucocyte-infiltrating populations in spleen, kidney and lung and kidney lesions, were measured. CO therapy significantly decreased the frequency of activated B220+ CD4- CD8- T cells in kidneys and lungs, as well as serum levels of ANA. Furthermore, we observed that CO therapy reduced kidney injury by decreasing proliferative glomerular damage and immune complexes deposition, decreased proinflammatory cytokine production and finally delayed the impairment of kidney function. CO exposure ameliorates kidney and lung leucocyte infiltration and delays kidney disease in MRL-Faslpr lupus mice. Our data support the notion that CO could be explored as a potential new therapy for lupus nephritis. |
| publishDate |
2015 |
| dc.date.none.fl_str_mv |
2015-07 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/210329 Mackern Oberti, Juan Pablo; Obreque, J.; Méndez, G. P.; Llanos, Carolina; Kalergis, Alexis; Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus; Oxford University Press; Clinical and Experimental Immunology; 7-2015; 1-13 0009-9104 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/210329 |
| identifier_str_mv |
Mackern Oberti, Juan Pablo; Obreque, J.; Méndez, G. P.; Llanos, Carolina; Kalergis, Alexis; Carbon monoxide inhibits T cell activation in target organs during systemic lupus erythematosus; Oxford University Press; Clinical and Experimental Immunology; 7-2015; 1-13 0009-9104 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1111/cei.12657 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Oxford University Press |
| publisher.none.fl_str_mv |
Oxford University Press |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1846782314512646144 |
| score |
12.982451 |